To understand why this matters, it helps to unpack what indexing in the Science Citation Index Expanded actually means. The Science Citation Index Expanded is one of the core citation databases maintained within the Web of Science, the citation ecosystem originally built on Eugene Garfield’s pioneering work at the Institute for Scientific Information. Inclusion is not automatic. Journals seeking coverage undergo a rigorous evaluation process in which publishers submit documentation of editorial standards, peer review practices, editorial board composition, publication ethics policies, and the international diversity of authorship. Clarivate’s editorial development team assesses whether the journal meets the quality thresholds for foundational coverage and whether its citation performance justifies admission. Being accepted into SciSearch in 2021 signaled that the Journal of Pharmaceutical Investigation had cleared one of the most demanding quality gates in scholarly publishing, a gate that thousands of journals worldwide never pass.

Indexing, in turn, is the precondition for the metric that has become the lingua franca of journal evaluation: the Impact Factor. Calculated annually by Clarivate from the Journal Citation Reports, the Impact Factor for a given year counts the number of citations received in that year by items published in the journal during the two preceding years, divided by the number of citable items published in those same two years. A value of 5.5 for 2022 therefore means that, on average, each citable article published in the journal during 2020 and 2021 was cited 5.5 times in 2022. Because the journal entered SciSearch in 2021, this figure reflects a relatively early citation window, which makes the performance even more striking. New entrants to the citation index typically take several years to accumulate visibility, so a first-quartile placement so soon after admission suggests an unusually rapid adoption by the research community.

The quartile classification adds another layer of meaning. Clarivate assigns journals to categories, and within each category journals are ranked by their Impact Factor and divided into quartiles, with Q1 representing the top 25 percent of titles. The Pharmacology and Pharmacy category is one of the largest and most competitive in the entire Web of Science taxonomy, encompassing 278 journals that range from mega-journals of translational medicine to highly specialized publications in toxicology, drug metabolism, and clinical pharmacy. Ranking 48th in that field places the Journal of Pharmaceutical Investigation firmly within the upper tier of pharmacological publishing, alongside far more established titles with decades of citation history. For authors weighing where to submit manuscripts, quartile placement often carries practical consequences, because funding agencies, promotion committees, and doctoral programs in many countries explicitly require publication in Q1 journals.

The journal’s subject scope helps explain its rising citation profile. Pharmaceutical investigation as a discipline sits at the crossroads of pharmaceutics, biopharmaceutics, drug delivery, pharmacokinetics, and formulation science, and it increasingly absorbs techniques from nanotechnology, materials science, and computational modeling. Research published under this umbrella includes studies of controlled-release systems, lipid-based carriers, polymeric nanoparticles, dissolution testing, bioavailability enhancement, and the physicochemical characterization of novel dosage forms. In recent years the field has been swept up in broader currents reshaping the pharmaceutical sciences, including the explosion of interest in mRNA delivery platforms, the refinement of long-acting injectable formulations, and the application of machine learning to formulation optimization. Journals positioned at the center of these currents tend to attract high citations, because their articles serve as methodological references for large and fast-moving research communities.

The journal in question is published by Springer, one of the major international scientific publishers, and the pharmaceutical sciences have long been a strategic area for the company’s portfolio. The relationship between publisher and index provider is central to the economics of modern scholarly communication. Publishers invest in editorial infrastructure, peer review management, digital preservation, and dissemination platforms, while citation index providers aggregate the resulting literature into evaluative frameworks that institutions use to allocate resources. The feedback loop can be powerful. Indexing increases discoverability through Web of Science searches, discoverability drives downloads and citations, and citations raise the Impact Factor, which in turn attracts stronger submissions from researchers seeking maximum visibility for their work. The journal’s 2022 numbers suggest that this flywheel has begun to turn decisively.

It is worth pausing on how rapidly scholarly metrics themselves have evolved, because the Impact Factor, despite its ubiquity, is a blunt instrument. Critics have long noted that the two-year citation window disadvantages slow-moving fields, that citation distributions within journals are heavily skewed so that a small fraction of papers accounts for most citations, and that aggregate scores can be gamed through editorial strategies such as publishing review articles, which attract citations at a higher rate than primary research. The San Francisco Declaration on Research Assessment, signed by thousands of journals and institutions, urges evaluators to look past journal-level metrics to the actual content and quality of individual papers. Yet the practical reality in much of the world, particularly in Asia, Europe, and Latin America, is that Impact Factors and quartiles remain embedded in grant applications, hiring decisions, and national research assessment exercises. Against that backdrop, a journal’s climb into Q1 translates directly into the career incentives of working scientists.

The pharmaceutical sciences occupy a distinctive position in this evaluative landscape because the field straddles academia and industry. Research on drug delivery and formulation frequently progresses from laboratory bench to clinical application, and the intellectual property and commercial stakes involved mean that citation patterns differ from those in purely academic disciplines. Industry scientists read and cite the pharmaceutical technology literature when designing development programs, and regulatory science considerations, such as bioequivalence standards and dissolution specifications, generate steady citation demand for foundational methodology papers. A Q1 journal in this space therefore functions not only as an academic outlet but as a shared reference point connecting university labs, contract research organizations, generic drug manufacturers, and innovator pharmaceutical companies across dozens of countries.

The timeline of the journal’s ascent is also instructive for understanding how new journals break through in a crowded market. Acceptance into SciSearch in 2021 followed the standard probationary logic of the Web of Science: emerging journals receive partial coverage initially, typically tracking newly published content, and their citation records build as indexed material accumulates. Within a single full cycle the journal achieved an Impact Factor of 5.5 and a category rank of 48 of 278, performance that many long-established titles would consider strong. This acceleration is characteristic of the current era, in which digital distribution, social media amplification, and global submission pipelines allow a well-edited journal to reach its audience far faster than was possible in the print-dominated decades when citation reputations took a generation to form.

For observers of scientific publishing, the broader lesson is that the map of influential journals is not fixed. The Pharmacology and Pharmacy category continues to expand, the tools for evaluating research continue to evolve, and the competition for high-quality manuscripts intensifies as publishers launch new open-access titles and established journals adjust their strategies. The Journal of Pharmaceutical Investigation’s 2022 standing, with an Impact Factor of 5.5 and a first-quartile ranking among 278 pharmacology journals, demonstrates how indexing prestige, editorial focus, and community engagement combine to reshape that map. Whether the journal can sustain and improve its position in future Journal Citation Reports will depend on the same factors that drive all scholarly success: the quality and novelty of the science it publishes, the rigor of its peer review, and its ability to serve as an indispensable resource for the researchers advancing drug development worldwide.

Subject of Research: Indexing and citation performance of the Journal of Pharmaceutical Investigation in the Web of Science Pharmacology and Pharmacy category

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Impact Factor, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, quartile ranking, citation metrics, drug delivery, pharmaceutical sciences, Springer, Q1 journal

Rimer’s investigation overturns conventional paradigms in crystallography by demonstrating that natural bending and twisting in crystals can be induced purely through the internal molecular rearrangements of tautomers, a class of molecules capable of rapid atomic shuffling. These tautomers exhibit the remarkable ability to reposition hydrogen atoms and adjust their atomic configurations spontaneously, introducing localized defects in the crystal lattice that manifest in macro-scale curvature without external manipulation.

The implications of this discovery resonate profoundly within the pharmaceutical industry, where about 30 of the top 200 drugs are composed of tautomeric molecules. The team’s insights suggest that by understanding and controlling tautomer-induced defects, it may be possible to tailor drug delivery mechanisms with unprecedented precision. Alterations in crystal shape and morphology directly influence dissolution rates, drug bioavailability, and pharmacokinetics, potentially revolutionizing how active pharmaceutical ingredients are formulated for enhanced therapeutic performance.

This breakthrough was meticulously detailed in the latest edition of the Proceedings of the National Academy of Sciences, where Rimer and his collaborators presented compelling evidence of natural, controlled bending arising from the formation of crystal defects such as twins, screw, and edge dislocations. Such defects emerge as a byproduct of the minor tautomer’s role as a growth modifier during crystallization, underscoring the nuanced interplay between molecular chemistry and crystal plasticity.

At the heart of this research lies an innovative approach combining state-of-the-art microscopic and spectroscopic techniques, which allowed the team to visualize and quantify the structural changes within the crystals at multiple length scales. By fine-tuning growth conditions, the researchers demonstrated the ability to modulate the extent of curvature, paving the way for engineered crystals with customized shapes and mechanical properties.

The significance of bending and twisting molecular crystals extends beyond pharmaceuticals, with potential applications spanning optoelectronics, soft robotics, and smart sensors. Materials engineered for flexibility and dynamic response could lead to the next generation of adaptive electronics and responsive biomaterials, where mechanical deformation plays a critical role in function and efficiency.

Rimer emphasizes that this mechanistic understanding offers a gateway to crystal engineering strategies that harness naturally occurring molecular phenomena for precise material design. By exploiting tautomerism-induced defects, scientists may develop novel pathways for fabricating crystals with complex morphologies unattainable through traditional methods reliant on physical deformation or external forces.

Moreover, the research reveals new insights into pathological crystallization, shedding light on how defects generated through minor tautomer populations might influence the formation of unique crystal morphologies observed both in synthetic environments and biological systems. This cross-disciplinary revelation opens a frontier where chemistry meets biology, deepening our comprehension of growth processes that dictate material properties on a fundamental level.

The pioneering work is supported by the Welch Center for Advanced Bioactive Materials Crystallization, a research hub established at the University of Houston in 2023 with a generous $5 million grant from the Welch Foundation. This center not only fosters cutting-edge investigations like Rimer’s but also facilitates collaboration across institutions and industry partnerships, anchoring Texas as a forefront of chemical research excellence.

Recent initiatives by the Welch Center, including symposia featuring an industrial advisory board created by major pharmaceutical players and summer crystallization camps for budding scientists, underscore a commitment to nurturing the next generation of innovators in materials science and drug development.

The ability to control crystal morphology through tautomerism challenges longstanding notions in condensed matter physics and crystallography. By manipulating atomic rearrangements and crystal plasticity at the molecular level, Jeffery Rimer’s research establishes a compelling platform for future explorations into adaptive materials and transformative pharmaceutical technologies.

This remarkable work charts a new course for the science of crystals, illustrating that molecular gymnastics within the crystal lattice constitute a hidden arsenal for material engineers seeking to introduce flexibility, sophistication, and functionality into traditionally rigid structures. The marriage of tautomer chemistry with crystal growth dynamics thus heralds a paradigm shift with implications rippling across applied sciences and healthcare.

Subject of Research: Tautomerism-induced natural bending and twisting in biogenic crystals and its applications in material science and pharmaceuticals.

Article Title: Tautomerism induces bending and twisting of biogenic crystals

References: Reported in the journal Proceedings of the National Academy of Sciences (PNAS)

Image Credits: University of Houston

At the core of this research lies the challenge of overcoming the skin barrier, which traditionally poses a significant obstacle for the systemic absorption of drugs. The skin’s outermost layer, the stratum corneum, serves as a formidable barrier, limiting the passive diffusion of many drugs. In their meticulous work, Tran and colleagues investigate how NLCs can be engineered to enhance drug permeation through this barrier. By using lipid matrices at the nanoscale, their approach not only aims to protect the active pharmaceutical ingredients but also to facilitate their controlled release directly into the systemic circulation.

In the foundational stages of developing NLCs, it is essential to understand their composition. NLCs are essentially composed of solid and liquid lipids, which provide a unique structure conducive to drug entrapment. The researchers highlight that this dual-lipid composition presents significant advantages, including improved stability, prolonged release profiles, and enhanced bioavailability of drugs. By selecting the appropriate types of lipids, formulations can be tailored for specific therapeutic agents, broadening the applicability of this technology across various medical conditions.

The actual application of NLCs in transdermal drug delivery necessitates a thorough understanding of their physicochemical properties. Tran et al. meticulously examine parameters such as particle size, charge, and morphology—factors that critically affect skin permeability. Their results indicate that smaller, uniformly sized lipid carriers significantly improve skin penetration compared to larger aggregates. Furthermore, the surface charge of NLCs plays a pivotal role in their interaction with skin membranes. The strategic manipulation of these characteristics opens a pathway to enhancing the clinical effectiveness of transdermal therapies.

One of the highlights of Tran’s study is the in vitro and in vivo models employed to evaluate the effectiveness of NLCs in drug delivery. Through extensive experimentation, the researchers underscore the importance of simulating real-world conditions to observe how NLCs behave upon application to the skin. Their findings corroborate the hypothesis that NLCs not only aid in drug penetration but also provide a reservoir effect, gradually releasing the drug over time, which helps maintain therapeutic plasma levels for extended periods.

As the investigation progresses, the therapeutic candidates being tested with NLCs range from anti-inflammatory agents to analgesics and beyond. The fabric of the pharmaceutical landscape is shifting as researchers leverage the versatility of NLCs. Tran and colleagues emphasize that these lipid carriers can potentially reformulate existing drugs that currently struggle with bioavailability, thus revitalizing them for a new lease on therapeutic life. The ramifications of such advancements could lead to groundbreaking treatments that deliver consistent outcomes in chronic disease management.

Additionally, Tran et al. address the regulatory challenges posed by the introduction of nanotechnology in drug development. These challenges often stem from the need to assess the safety and efficacy of nanoscale formulations rigorously. The authors provide insight into possible regulatory pathways to streamline the approval of NLC-based products. They argue for collaborative frameworks between researchers, regulatory bodies, and industry stakeholders to ensure that advancements do not stall in the face of bureaucracy, allowing for quicker transitions from bench to bedside.

In the broader picture, the implications of their findings extend beyond immediate therapeutic applications. The potential for integrating NLCs into personalized medicine paradigms is especially poignant. As patients increasingly seek customized solutions tailored to their specific health profiles, NLCs present an ideal vehicle for this personalized approach. The study suggests that the versatility in tailoring drug formulations with NLCs may lead to more effective personalized treatment regimens in the foreseeable future.

Moreover, the researchers also touch upon the sustainability factor in the design of NLCs. In an age where environmental considerations are paramount, the ability to utilize biocompatible and biodegradable materials in the formulation process adds another layer of appeal. As the pharmaceutical industry seeks to minimize its ecological footprint, the development of NLCs from natural lipids resonates with global sustainability goals. This alignment not only enhances acceptance among consumers and healthcare professionals but may also bolster the market potential of NLC-based therapies.

As the journey of nanostructured lipid carriers progresses, Tran, Dao, and Nguyen’s contributions catalyze a wave of enthusiasm within the scientific community. Their study marks a significant stride toward realizing the potential of NLCs in medical science, particularly concerning their role in transdermal drug delivery. The collaborative efforts of researchers and clinicians continue to embody the spirit of innovation that drives the field forward, reshaping the landscape of drug administration practices.

In conclusion, the research conducted by Tran et al. underscores the transformative power of nanotechnology in pharmaceutical sciences. The application of nanostructured lipid carriers not only addresses existing barriers to efficient drug delivery but also resonates with the broader themes of personalized medicine, sustainability, and collaborative innovation. As this exciting field of study evolves, it holds the promise of improving patient care globally, fostering a healthier future for generations to come.

Subject of Research: Nanostructured lipid carriers in transdermal drug delivery

Article Title: Application of nanostructured lipid carriers for transdermal drug delivery

Article References:

Tran, T., Dao, T., Nguyen, H. et al. Application of nanostructured lipid carriers for transdermal drug delivery.
J. Pharm. Investig. (2025). https://doi.org/10.1007/s40005-025-00775-1

Image Credits: AI Generated

DOI: 10.1007/s40005-025-00775-1

Keywords: Nanostructured lipid carriers, transdermal drug delivery, bioavailability, drug formulation, personalized medicine.